InVivo Therapeutics Holdings Corporation
Other OTCTotal Valuation
InVivo Therapeutics Holdings Corporation carries a market capitalization of 1.15M, placing it among publicly traded companies globally. Its enterprise value stands at -5.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.15M |
| Enterprise Value | -5.24M |
Share Statistics
InVivo Therapeutics Holdings Corporation currently has 3.11M shares outstanding.
| Shares Outstanding | 3.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | -0.33 |
| P/OCF Ratio | -0.33 |
Financial Position
InVivo Therapeutics Holdings Corporation maintains a current ratio of 14.30, meaning it holds 14.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.30 |
| Quick Ratio | 12.88 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -81.32 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
InVivo Therapeutics Holdings Corporation's stock has declined approximately -70.63492% over the past 52 weeks. The 50-day moving average sits at 0.38, while the 200-day moving average is 0.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -70.63492% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.56 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.44M, while operating income came in at -9.86M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.86M |
| Pretax Income | -9.33M |
| Net Income | -9.33M |
| EBITDA | -9.44M |
| EBIT | -9.86M |
| Earnings Per Share (EPS) | -3.13 |
Balance Sheet
Total book value stands at -255.58M, with working capital of 8.86M providing operational flexibility.
| Cash & Cash Equivalents | 8.58M |
| Total Debt | N/A |
| Net Debt | -8.58M |
| Equity (Book Value) | -255.58M |
| Book Value Per Share | -85.69 |
| Working Capital | 8.86M |
Cash Flow
InVivo Therapeutics Holdings Corporation produced -10.13M in operating cash flow over the past twelve months. After subtracting -45,000.00 in capital expenditures, free cash flow totaled -10.17M - equivalent to -3.41 per share.
| Operating Cash Flow | -10.13M |
| Capital Expenditures | -45,000.00 |
| Free Cash Flow | -10.17M |
| FCF Per Share | -3.41 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -238.35 |
| FCF Yield | -301.84 |
Stock Splits
InVivo Therapeutics Holdings Corporation's most recent stock split took place on April 27, 2022 with a 25:1 split ratio.
| Last Split Date | 4/27/2022 |
| Split Ratio | 25:1 |
Scores
InVivo Therapeutics Holdings Corporation posts an Altman Z-Score of -36.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -36.61 |